W. Paul Dmowski

No ORCID on file · 94 papers in corpus · active 1969-2018

Study types

  • article 78
  • book-chapter 8
  • review 4
  • letter 3
  • rct 1

Condition tags

  • endometriosis 86
  • infertility 9
  • chronic_pelvic_pain 5
  • dysmenorrhea 4
  • dyspareunia 2
  • endometrioma 1
article 2018
Long-Term Outcomes of Elagolix in Women With Endometriosis
Obstetrics and gynecology ·doi:10.1097/aog.0000000000002675

OBJECTIVE: To evaluate the efficacy and safety of elagolix, an oral, nonpeptide gonadotropin-releasing hormone antagonist, over 12 months in women with endometriosis-associated pain. METHODS: Elaris Endometriosis (EM)-III and -IV were exten…

article 2018
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
·doi:10.1530/ey.15.15.6

We highlight this paper for 3 reasons. First, remarkably there are few robust data on effective treatment options for endometriosis. Subcutaneous GnRH antagonists are sometimes used off-label, but with very limited evidence. Secondly, the c…

rct 2017
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
The New England journal of medicine ·doi:10.1056/NEJMoa1700089

BACKGROUND: Endometriosis is a chronic, estrogen-dependent condition that causes dysmenorrhea and pelvic pain. Elagolix, an oral, nonpeptide, gonadotropin-releasing hormone (GnRH) antagonist, produced partial to nearly full estrogen suppres…

article 2017
Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
·doi:10.1056/nejmoa1700089

Copyright © 2017 Massachusetts Medical Society. BACKGROUND Endometriosis is a chronic, estrogen-dependent condition that causes dysmenorrhea and pelvic pain. Elagolix, an oral, nonpeptide, gonadotropin-releasing hormone (GnRH) antagonist, …

article 2014
Elagolix, an Oral GnRH Antagonist, Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis: Effects on Bone Mineral Density
Reproductive sciences (Thousand Oaks, Calif.) ·doi:10.1177/1933719114549848

This randomized double-blind study, with 24-week treatment and 24-week posttreatment periods, evaluated the effects of elagolix (150 mg every day, 75 mg twice a day) versus subcutaneous depot medroxyprogesterone acetate (DMPA-SC) on bone mi…

article 2013
Elagolix, an Oral GnRH Antagonist for Endometriosis-Associated Pain: A Randomized Controlled Study
Journal of endometriosis and pelvic pain disorders ·doi:10.5301/je.5000157

OBJECTIVE: The aim of this study was to estimate the efficacy of elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist, for the treatment of endometriosis-associated pelvic pain. METHODS: This was a phase II, randomized, placeb…

article 2013
Elagolix Treatment for Endometriosis-Associated Pain: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Reproductive sciences (Thousand Oaks, Calif.) ·doi:10.1177/1933719113497292

This Phase 2 study evaluated the safety and efficacy of elagolix for treating endometriosis-associated pain. A total of 155 women with laparoscopically confirmed endometriosis were randomized to placebo, elagolix 150 mg, or elagolix 250 mg …

article 2010
10 SYMPTOMS OF ENDOMETRIOSIS; PATHOLOGIC BASIS
·doi:10.1016/s1472-6483(10)62428-5
article 2010
11 EFFECT OF LAPAROSCOPIC SURGERY ON OVARIAN FUNCTION IN WOMEN WITH ENDOMETRIOSIS
·doi:10.1016/s1472-6483(10)62429-7
article 2010
COMT Val-158-met gene polymorphism is not associated with endometriosis-related pain
·doi:10.1016/j.fertnstert.2010.07.801
article 2008
New concepts in pathogenesis of endometriosis
·doi:10.1016/s1472-6483(11)60640-8
article 2007
Association between COMT gene polymorphism and endometriosis-associated pain: an interim analysis
·doi:10.1016/j.fertnstert.2007.07.726
article 2007
Immunohistochemical detection of heparanase-1 expression in eutopic and ectopic endometrium from women with endometriosis
Fertility and sterility ·doi:10.1016/j.fertnstert.2006.12.081

ObjectiveTo investigate the expression of heparanase-1, an endoglycosidase that degrades heparan sulfate proteoglycans, in eutopic and ectopic endometrial tissues from women with endometriosis.DesignAn immunohistochemical study.SettingAcade…

article 2006
P-383
·doi:10.1016/j.fertnstert.2006.07.740
article 2006
Quantitative expression of apoptosis-regulating genes in endometrium from women with and without endometriosis
Fertility and sterility ·doi:10.1016/j.fertnstert.2006.06.026

ObjectiveTo quantitate antiapoptotic and proapoptotic gene expression in endometrial cells (ECs) of women with and without endometriosis.DesignDetermination of transcript abundance (TA) of apoptosis-regulating genes in eutopic and ectopic e…

article 2005
Quantitative Expression of Growth Regulatory Genes in Matched, Eutopic and Ectopic Endometrial Cells from Women with Endometriosis
·doi:10.1016/j.fertnstert.2005.07.486
book-chapter 2005
Should In Vitro Fertilization/Embryo Transfer (IVF/ET) be the First-line Approach to the Management of Infertility in Women with Endometriosis?
·doi:10.5005/jp/books/10334_6
article 2004
Heparanase-1 gene expression and regulation in the endometrium from women with and without endometriosis during different phases of the cycle
·doi:10.1016/j.fertnstert.2004.07.194
review 2004
Immunology of endometriosis
Best practice & research. Clinical obstetrics & gynaecology ·doi:10.1016/j.bpobgyn.2004.02.001

Endometriosis is a benign gynecologic disorder characterized by the ectopic growth of misplaced endometrial cells. A unifying hypothesis to explain endometriosis has not been elucidated as yet but numerous investigations have implicated dis…

article 2004
The effects of endometrioma resection on subsequent ovarian stimulation and fertilization/embryo transfer (IVF/ET) success rates
·doi:10.1016/j.fertnstert.2004.07.092
article 2003
Differential Hypoxia-Inducible Factor (HIF)-1α expression in endometrium from women with and without endometriosis
·doi:10.1016/s0015-0282(03)01507-3
book-chapter 2003
Endometriosis
·doi:10.1016/b978-012053642-9/50031-4
article 2003
Genomic response of endometrial cells to TNF-alpha stimulation in women with endometriosis
·doi:10.1016/s0015-0282(03)01499-7
article 2002
Cumulative pregnancy rates with IVF/ET and COH/AIH in endometriosis: should IVF/ET be the first line of treatment in the management of infertility in this population?
·doi:10.1016/s0015-0282(01)03043-6
article 2002
Cycle-specific and cumulative fecundity in patients with endometriosis who are undergoing controlled ovarian hyperstimulation-intrauterine insemination or in vitro fertilization-embryo transfer
Fertility and Sterility ·doi:10.1016/s0015-0282(02)03343-5

ObjectiveTo compare controlled ovarian hyperstimulation-intrauterine insemination (COH-IUI) or IVF-ET pregnancy rates per cycle (PR) and cycle and cumulative fecundity (f and cf) with COH-IUI or IVF-ET in endometriosis.DesignRetrospective a…